Essilor's 2007 Third-Quarter Report(back 400000 Oceaneconvertible bonds due ...)

Date:10/23/2007

back 400,000 Oceane convertible bonds due 2010, representing the equivalent of 800,000 shares. Representing 7% of the original 2003 issue, the 400,000 bonds were bought back at a total cost of EUR35.9 million. Following these transactions, there are currently 4,845,264 bonds outstanding, representing 80.2% of the original issue.

During the third quarter, the Company also bought back 500,000 Essilor shares for EUR22 million. These shares will be cancelled.

The buybacks are part of the policy implemented by the Company since 2003 to offset the dilution resulting from its stock option and performance share grant plans.

Cash position

During the third quarter, Essilor's net cash position increased by some EUR90 million. This increase, which was achieved despite the high level of financial investment and capital expenditure, was in line with the trend observed in prior years due to the normal seasonal fluctuations in business.

A conference call will be held today at 10:00 a.m. CET.

The number to dial is: +44-(0)161-601-8918

The conference will be available for later listening at:

http://hosting.3sens.com/Essilor/20071024-19A92C3C/en/

2008 financial calendar

2007 revenue announcement: Thursday, January 24, 2008

2007 results announcement: Thursday, March 6, 2008

Essilor International is the world leader in ophthalmic optical products, offering a wide range of lenses under the flagship Varilux(R), Crizal(R), Airwear(R), Essilor(R) and Definity(TM) brands to correct myopia, hyperopia, presbyopia and astigmatism. Essilor operates worldwide through 15 production sites, 244 lens finishing laboratories and local distribution networks. The Essilor share trades on the Euronext Paris market and is included in the CAC 40 index. (ISIN: FR 0000121667; Reuters: ESSI.PA; Bloomberg: EF:FP).

Investor Relations and Financial Commun
'/>"/>

SOURCE Essilor Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Third Wave Reports Third-Quarter Financial Results
2. GE Healthcare third-quarter profits up 17 percent
3. Midwest small-cap life sciences turn in mixed third-quarter results
4. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
5. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
6. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
7. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
8. Versatile Reporter Vectors for Monitoring Viral Transduction
9. In Vivo Signal Transduction Pathway Reporting Systems
10. Improved Vectors for PathDetect Trans-Reporting Systems
11. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways